Last reviewed 2026-06-01 · How we verify

pentetrazol

unknown active ✓ Verified Jun 2026

pentetrazol is a drug. It is currently in unknown development.

Pentetrazol, also known as pentylenetetrazole, is a small molecule drug that has been used in the past as a circulatory and respiratory stimulant. It has been studied as a potential treatment for idiopathic hypersomnia in a clinical trial, where it was compared to a placebo in a randomized, double-blind, crossover study.

At a glance

Generic name	pentetrazol
Therapeutic area	Other
Phase	unknown

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

pentetrazol CI brief — competitive landscape report
pentetrazol updates RSS · CI watch RSS
portfolio CI

Frequently asked questions about pentetrazol

What is pentetrazol?

pentetrazol is a pharmaceutical drug.

What development phase is pentetrazol in?

pentetrazol is in unknown.

Manufacturer: — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing